<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="163777">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00966082</url>
  </required_header>
  <id_info>
    <org_study_id>EBLPPL-2</org_study_id>
    <nct_id>NCT00966082</nct_id>
  </id_info>
  <brief_title>Endoscopic Band Ligation (EBL) Versus Endoscopic Band Ligation and Propranolol for the Prevention of Variceal Rebleeding in Pts With Previous Variceal Treatment</brief_title>
  <official_title>RCT Comparing the Efficacies of Endoscopic Band Ligation (EBL) and Combined Treatment of Beta-blocker and EBL for the Prevention of Esophageal Variceal Rebleeding in Patients With Previous Endoscopic Variceal Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Both propranolol and endoscopic band ligation (EBL) are effective for prevention of variceal
      rebleeding. Recently several studies compared the efficacy of EBL alone and with a
      combination of propranolol and EBL. However, the results of recent studies showed
      discrepancy. In addition, most of all recent studies included patients without previous
      endoscopic treatment for varices. This study is performed to compare the efficacy and safety
      of EBL alone and EBL combined with propranolol in patients who were previously performed
      endoscopic variceal treatment.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2008</start_date>
  <completion_date type="Anticipated">July 2013</completion_date>
  <primary_completion_date type="Anticipated">July 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rebleeding from esophageal varices</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Upper gastrointestinal bleeding; Significant esophageal variceal bleeding; Mortality; Adverse events</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Cirrhosis</condition>
  <condition>Variceal Bleeding</condition>
  <arm_group>
    <arm_group_label>Endoscopic band ligation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Perform endoscopic band ligation (EBL) until eradication of esophageal varices, and then follow-up endoscopy with 3-6 months interval</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EBL+Propranolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EBL</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>endoscopic band ligation</intervention_name>
    <description>Perform EBL until esophageal varices are eradicated, and then follow-up endoscopy with 3-6 months interval</description>
    <arm_group_label>Endoscopic band ligation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endoscopic band ligation and propranolol</intervention_name>
    <description>Perform EBL until esophageal varices are eradicated, and then follow-up endoscopy with 3-6 months interval
Active Comparator: EBL+Propranolol Perform EBL same as EBL group. In addition, take propranolol to reduce 25% in HR or HR â‰¤55/min</description>
    <arm_group_label>EBL+Propranolol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Liver cirrhosis

          -  Age between 18 and 70 years

          -  Successful control of esophageal variceal bleeding within 6 weeks before enrollment

        Exclusion Criteria:

          -  Gastric variceal bleeding

          -  Patients with systolic blood pressure &lt;100 mmHg or basal heart rate &lt;60/min

          -  Portal vein thrombosis

          -  Prominent hepatic encephalopathy

          -  Coexisting untreated malignancy

          -  Severe cerebrovascular or cardiovascular disease, renal failure

          -  No previous history of endoscopic, radiologic, or surgical treatment for varices or
             ascites

          -  Contraindication to beta-blocker

          -  Pregnancy

          -  Refusal to give consent to participate in the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Soon Ho Um, Prof</last_name>
    <phone>82-2-920-5019</phone>
    <email>umsh@korea.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yeon Seok Seo, MD</last_name>
    <phone>82-2-920-6608</phone>
    <email>drseo@korea.ac.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>136-705</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <lastchanged_date>August 25, 2009</lastchanged_date>
  <firstreceived_date>August 25, 2009</firstreceived_date>
  <responsible_party>
    <name_title>Liver Cirrhosis Clinical Research Center, Division of Gastroenterology and Hepatology, Department of Internal Medicine</name_title>
    <organization>Korea University Anam Hospital</organization>
  </responsible_party>
  <keyword>Cirrhosis</keyword>
  <keyword>Esophagus Disorders</keyword>
  <keyword>Varicose Veins</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Propranolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
